|
|
|
| Correlation between the levels of serum placental growth factor，pregnancy associated plasma protein-A, and β-human chorionic gonadotropin of pregnant women and the occurrence of hypertensive disorder complicating pregnancy and their values for predicting the adverse pregnancy outcomes of the women |
| Copital Medical University Daxing Teaching Medicine，Beijing, 102600 |
|
|
|
|
Abstract To detect the expression of placental growth factor (PLGF)，pregnancy associated plasma protein-A (PAPP-A), and β-human chorionic gonadotropin (β-HCG) of pregnant women, and to explore the correlation between the levels of PLGF, PAPP-A, β-HCG of the women and their occurrence of hypertensive disorder complicating pregnancy. Methods：From February 2019 to July 2021，127 pregnant women with hypertensive disorder complicating pregnancy who were registered and had accepted regular antenatal examination were selected in study group，and were divided into group A ( women with pregnancy induced hypertension), group B ( women with mild preeclampsia)，and group C ( women with severe preeclampsia). 160 normal pregnant women were selected in control group during the same period. Enzyme linked immunosorbent assay was used to detect the expression levels of serum PLGF and PAPP-A, and automatic chemiluminescence immunoassay analyzer was used to detected the serum level of β-HCG. Pearson method was used to analyze the correlation between the levels of serum PLGF，PAPP-A，β-HCG of the women with hypertensive disorder complicating pregnancy and their adverse pregnancy outcomes. Receiver operating characteristic（ROC）curve was used to analyze the value of the levels of serum PLGF，PAPP-A，β-HCG of the women for predicting their adverse pregnancy outcomes, and Logistic regression analysis was used to analyze the related factors affecting the adverse pregnancy outcomes. Results：The levels of PAPP-A and β-HCG of the women in group A, group B, and group C had increased gradually, and which were significantly higher than those of the women in the control group. The level of PLGF of the women in group A, group B, and group C had decreased gradually, and which was significantly lower than that of the women in the control group (all P<0.05). The rates of fetal growth restriction, fetal distress, and preterm delivery of the women in the study group were significantly higher than those of the women in the control group (P<0.05). The serum PLGF level of the women with adverse pregnancy outcomes was significantly lower than that of the women with normal pregnancy outcomes, and the levels of serum PAPP-A and β-HCG of the women with adverse pregnancy outcomes were significantly higher (all P<0.05). The serum PLGF level of the women was negatively correlated with the rates of their fetal growth restriction, fetal distress, and preterm delivery, while the serum PAPP-A and β-HCG levels of the women were positively correlated with the rates of their fetal growth restriction, fetal distress, and preterm delivery (all P<0.05). The area under the curve of the combined serum PLGF, PAPP-A, and β-HCG levels for predicting the occurrence of adverse pregnancy outcomes of the women in the study group was 0.929, which was significantly higher than that of the serum PLGF level, PAPP-A level, or β-HCG level alone (P<0.05). The high level of serum PLGF was a protective factor of the adverse pregnancy outcomes of the women, and the high levels of serum PAPP-A and β-HCG were the independent risk factors of the adverse pregnancy outcomes of the women. Conclusion：The expression levels of serum PLGF, PAPP-A, andβ-HCG of the pregnant women with hypertensive disorder complicating pregnancy were abnormal, which are closely related to their occurrence of adverse pregnancy outcomes. The levels of serum PLGF，PAPP-A, and β-HCG can be used as the potential biological indicators to evaluate the adverse pregnancy outcomes of the pregnant women with hypertensive disorder complicating pregnancy.
|
|
|
|
|
|
|
|
|
